Related Experiment Video
Updated: Aug 15, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient
Milan Reinis1, Jana Símová, Jan Bubeník
1Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Abstract:
Unmethylated oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) have been described as potent inducers of selected antitumour immune responses and the immunotherapeutic efficacy of CpG ODN has been examined either alone or as a vaccine adjuvant. We hypothesized that CpG ODN therapy could be an effective tool for immunotherapy of not only conventional MHC class I(+) tumours but also of those tumours that have lost MHC class I expression during their progression. To address this hypothesis, we employed the animal model resembling MHC class I-proficient and -deficient human papilloma virus (HPV) 16-associated tumours. A cell line transformed with HPV16 E6 and E7 oncogenes, TC-1, as a prototype of MHC class I-positive line, and its MHC class I-deficient sublines TC-1/A9 and TC-1/P3C10 were injected into syngeneic C57BL/6 mice and the growing tumours were subjected to immunotherapy with CpG ODN 1826. The therapy started either 1 day after the challenge with the tumour cells or later, when the tumours had reached a palpable size. In both settings, CpG ODN 1826 significantly reduced the growth of MHC class I-proficient and -deficient tumours. Furthermore, we demonstrated that CpG ODN 1585, whose mechanism of action preferably involves indirect activation of the natural killer cells, induced regression of the MHC class I-deficient tumours TC1/A9 but not of the MHC class I-proficient tumours TC-1. This study infers that synthetic CpG ODN have a potential for the therapy of both MHC class I-proficient and -deficient tumours and thus could be also used against tumours that tend to down-regulate their MHC class I expression.
Insights
Synthetic CpG oligodeoxynucleotides (ODN) show promise for treating various cancers. This immunotherapy effectively reduced both MHC class I-proficient and -deficient tumors, offering new hope for difficult-to-treat cancers.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Unmethylated oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are known immune response modifiers.
- CpG ODN have been explored as monotherapy and vaccine adjuvants for cancer immunotherapy.
- Tumor progression can involve the loss of MHC class I expression, potentially evading immune surveillance.
Purpose of the Study:
- To investigate the efficacy of CpG ODN therapy against tumors with and without MHC class I expression.
- To determine if CpG ODN can overcome immune evasion strategies related to MHC class I downregulation.
- To evaluate CpG ODN as a potential immunotherapy for a broad range of tumors, including those with altered MHC class I status.
Main Methods:
- Utilized a syngeneic mouse model with human papilloma virus (HPV) 16-associated tumors, including MHC class I-proficient (TC-1) and MHC class I-deficient (TC-1/A9, TC-1/P3C10) cell lines.
- Administered CpG ODN 1826 immunotherapy to mice bearing established or early-stage tumors.
- Tested CpG ODN 1585, focusing on natural killer (NK) cell activation, against both MHC class I-proficient and -deficient tumors.
Main Results:
- CpG ODN 1826 significantly inhibited the growth of both MHC class I-proficient and MHC class I-deficient tumors, regardless of treatment timing.
- CpG ODN 1585 induced regression of MHC class I-deficient tumors (TC1/A9) but not MHC class I-proficient tumors (TC-1).
- Demonstrated that CpG ODN therapy is effective even when tumors downregulate MHC class I expression.
Conclusions:
- Synthetic CpG ODN represent a viable immunotherapeutic strategy for both MHC class I-positive and MHC class I-negative tumors.
- CpG ODN therapy holds potential for treating cancers that downregulate MHC class I to escape immune detection.
- This approach broadens the applicability of CpG ODN immunotherapy to a wider spectrum of malignancies.
Related Concept Videos
02:23Abnormal Proliferation
01:22MicroRNAs
01:46Epigenetic Regulation
01:37Epigenetic Regulation
X-chromosome...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:19Inhibitors of Virion Maturation and Assembly